NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug ...

Cheryl Guerin of Enfield said her son, suffering from a chronic mental illness, would have been unable to survive without the “wraparound” services provided through the state’s FAST Forward program.

Wisconsin Fast Forward program offers $2.25 million in grant funds for health care training. Awards range from $5,000 to $400,000 to reimburse employers for developing training programs. Applications ...

Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, ...